Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Erythropoietin in Neonatal HIE
NCT06590155Phase 1Not yet recruiting
- Sponsor
- Assiut University
- Start
- Nov 2024
- Primary completion
- Feb 2029
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of erythropoietin in hypoxic-ischemic encephalopathy (HIE) (3 arms), sponsored by Assiut University. Primary endpoint: Oxygen saturation in neonates hypoxic ischemic encephalopathy after treatment. Planned start Nov 2024; status: not yet recruiting.
02
Drugs
erythropoietin
03
Conditions
hypoxic-ischemic encephalopathy (HIE)
Beyond the preview
Go deeper on NCT06590155.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06590155.